Moleculin Biotech

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, dedicated to developing innovative oncology drug candidates aimed at treating highly resistant tumors and viral infections. Its leading candidate, Annamycin, is a next-generation anthracycline currently undergoing Phase 1/2 trials for relapsed or refractory acute myeloid leukemia (AML) and lung metastases. The company also focuses on WP1066, an immune/transcription modulator in Phase 1 trials for brain tumors, pancreatic cancer, and glioblastoma. Other compounds in development include WP1220, which has completed Phase 1 trials for cutaneous T-cell lymphoma, WP1234 for pancreatic cancer, WP1732 for AML and other cancers, and WP1122, a metabolism/glycosylation inhibitor targeting cancers and viruses. Moleculin Biotech collaborates with prestigious institutions, including The University of Texas MD Anderson Cancer Center and Mayo Clinic Research Endeavor, to advance its drug candidates. Founded in 2015, the company continues to expand its portfolio while addressing significant unmet medical needs in oncology.